Lung Cancer and Mesothelioma CPG Mini Module – Immunotherapy for Lung Cancer in Challenging Populations

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

This mini module begins with a case presentation by Charu Aggarwal, MD, MPH, of the University of Pennsylvania, on a patient with PD-L1 high lung cancer and brain metastases. Dr. Aggarwal, along with panelists Roy S. Herbst, MD, PhD, of Yale Cancer Center, Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, and Patrick Forde, MBBCh, of Johns Hopkins Medicine, use this case as a starting point to discuss the timing systemic immunotherapy with radiation therapy and the role of PD-L1 levels in determining treatment. Panelists also provide insights into risks and benefits associated with combination therapies of chemotherapy with immunotherapy and current clinical trials addressing these issues.

Run Time: 11 Minutes 50 Seconds

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021). 
 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.